Latest News - Amgen
Top Corporates Hub
Amgen
Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now?
10.04.2026 04:44
Amgen Inc. (NASDAQ:AMGN) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Amgen Inc. (NASDAQ:AMGN) is one of the most profitable value stocks to buy right now. On April 6, Amgen announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA for patients with moderate-to-severe active […]
Eli Lilly’s Foundayo Weight-Loss Pill Hits the Shelves. It’s a Turning Point for the Stock.
09.04.2026 17:27
Eli Lilly made progress in its battle for weight-loss dominance Thursday, releasing its once-daily GLP-1 pill broadly through pharmacies and telehealth providers. Foundayo, Lilly’s oral medication for chronic weight management, is now available through platforms including GoodRx, Amazon Pharmacy, and Weight Watchers. Lilly also offers the pill through LillyDirect, the drugmaker’s direct-to-consumer platform.
Viridian Therapeutics price target lowered to $36 from $40 at Truist
09.04.2026 12:32
Truist lowered the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to build momentum through the remainder of the year into mid-terms, the analyst tells investors in a research note. For the company, the firm no
Guggenheim Maintains Neutral on Amgen, Raises Price Target to $351
09.04.2026 09:46
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $347 to $351.
Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $350 Price Target
08.04.2026 08:52
Cantor Fitzgerald analyst Carter Gould reiterates Amgen (NASDAQ:AMGN) with a Neutral and maintains $350 price target.
Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition
08.04.2026 08:09
Amgen (NasdaqGS:AMGN) released Phase 3 data for a subcutaneous, on-body injector version of TEPEZZA for Thyroid Eye Disease. The trial showed strong efficacy and safety results for the on-body injector compared with the existing IV infusion approach. This new administration route offers an at home treatment option that could broaden TEPEZZA’s use as competition in Thyroid Eye Disease grows. For investors following NasdaqGS:AMGN, TEPEZZA sits in a key therapeutic area where convenience and...
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
06.04.2026 16:10
Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is currently developing its own treatment for the disease.
Under-the-skin Tepezza comparable to infused version in key study, Amgen says
06.04.2026 14:54
The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing.
Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints
06.04.2026 13:00
Amgen followed up on Viridian Therapeutics' sizable crash Monday, delivering positive results for its next-generation Tepezza.
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
06.04.2026 13:00
Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED). TEPEZZA OBI provides comparable efficacy to, and builds upon the success of, intravenous (IV) TEPEZZA, the first and only medicine approved for the treatment of TED, which has now treated more than 25,000 patients worldwide.
Amgen Announces Phase 3 Study Of TEPEZZA Meets Primary Endpoint In Moderate-To-Severe Active Thyroid Eye Disease; Demonstrates 77% Proptosis Response Rate
06.04.2026 09:05
Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
03.04.2026 14:17
The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion of the S&P 500, started in January 2021 as high as $175, when it was the height of the pandemic. Since then, it has dropped as much as ... This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen’s (AMGN) Risk‑Reward Profile
03.04.2026 02:12
In late March 2026, the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Amgen‑distributed Tavneos (avacopan), while Zai Lab separately announced a global collaboration with Amgen to test its DLL3‑targeting ADC alongside Amgen’s IMDELLTRA in extensive‑stage small cell lung cancer. These developments highlight the dual reality for Amgen of expanding its oncology footprint through external partnerships even as fresh safety concerns emerge around an...
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now?
02.04.2026 14:46
Amgen Inc. (NASDAQ:AMGN) is one of the best pharma stocks to invest in now. Amgen Inc. (NASDAQ:AMGN) announced on March 28 that Repatha® lowered the risk of first major adverse cardiovascular events in high-risk primary prevention patients without known significant atherosclerosis and with diabetes when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments. The […]
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
01.04.2026 11:30
SHANGHAI & CAMBRIDGE, Mass., April 01, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab’s investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen’s IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-stage small cell lung cancer
Zai Lab and Amgen Team Up to Test New Combo Treatment for Lung Cancer
01.04.2026 07:35
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ:AMGN) to evaluate Zai Lab's investigational delta-like ligand 3 (DLL3)-targeting antibody-drug
Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results
30.03.2026 13:19
Viridian Therapeutics stock crashed Monday on "positive, but lackluster" final-phase results for its thyroid eye disease treatment.
Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen”
30.03.2026 11:06
Amgen Inc. (NASDAQ:AMGN) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Amgen Inc. (NASDAQ:AMGN) is one of the largest drug companies in the world. The firm is currently developing the weight loss drug MariTide. Its shares are up by 11.9% over the past year and are up by 24% since Cramer […]
Reported Saturday, Amgen's Repatha Reduces 3-P MACE Risk By 31% In VESALIUS-CV Subgroup Analysis Of 3,655 High-Risk Diabetic Patients Without Prior Heart Attack Or Stroke
30.03.2026 02:24
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary PreventionVESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk
Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550
28.03.2026 07:17
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026. On March 19, 2026, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) saw its price target raised by Wells Fargo from $515 to $550. The firm’s analyst kept an Overweight rating on the shares. Wells Fargo anticipates a threefold growth in the market for […]